Rfviii
Hemophilia B
Bioverativ Therapeutics Inc.Dormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
25 Active assets in the Hemophilia B cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benefix Pfizer | Phase 4 | A |
Factor Ix CSL Behring | Phase 4 | BBB |
Rix-Fp CSL Behring | Phase 3 | BBB |
Fitusiran Genzyme, a Sanofi Company | Phase 3 | BBB |
Bax 326 Baxalta now part of Shire | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Rfviii is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →